Daiichi Sankyo (OTCMKTS:DSNKY) Issues FY 2026 Earnings Guidance

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) updated its FY 2026 earnings guidance on Monday. The company provided EPS guidance of 0.910-0.910 for the period, compared to the consensus EPS estimate of 1.040. The company issued revenue guidance of $14.5 billion-$14.5 billion, compared to the consensus revenue estimate of $13.4 billion.Get Daiichi Sankyo alerts:Daiichi Sankyo Stock Up 1.8%Is Merck Stock Undervalued After Its Colossal Earnings Growth?OTCMKTS DSNKY traded up $0.29 during trading on Monday, reaching $16.80. 32,410 shares of the company's stock were exchanged, compared to its average volume of 444,342. Daiichi Sankyo has a fifty-two week low of $15.56 and a fifty-two week high of $28.21. The company's fifty day simple moving average is $17.94 and its 200-day simple moving average is $20.47. The company has a current ratio of 2.69, a quick ratio of 1.85 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $31.83 billion, a PE ratio of 15.41, a P/E/G ratio of 0.85 and a beta of -0.25. Wall Street Analyst Weigh InSeparately, Zacks Research raised Daiichi Sankyo from a "strong sell" rating to a "hold" rating in a research note on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy".Read Our Latest Stock Report on DSNKYDaiichi Sankyo Company Profile (Get Free Report)Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs. Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.Featured ArticlesFive stocks we like better than Daiichi Sankyo3 Metals and Mining Stocks Riding the Commodity SupercycleCatching Falling Knives: Is Time to Buy These Beaten-Down Stocks?The Stars Are Aligning For Apple: Get Ready for $3003 Small-Cap Stocks to Buy as the Russell 2000 Extends Its RallyThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Daiichi Sankyo Right Now?Before you consider Daiichi Sankyo, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Daiichi Sankyo wasn't on the list.While Daiichi Sankyo currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here